Generic Name and Formulations:
Miglitol 25mg, 50mg, 100mg; tabs.
Indications for GLYSET:
Adjunct to diet in type 2 diabetes, alone or with a sulfonylurea.
Take with the first bite of each main meal. Initially 25mg three times daily; may start at 25mg once daily (to minimize GI effects) and gradually increase to 25mg three times daily. Increase to 50mg three times daily after 4–8 weeks; usual max 100mg three times daily.
Ketoacidosis. Inflammatory bowel disease. Colonic ulceration. Partial intestinal obstruction or predisposition thereof. Chronic intestinal diseases associated with marked disorders of digestion or absorption. Conditions that may deteriorate from increased intestinal gas formation.
Significant renal dysfunction (serum creatinine >2mg/dL): not recommended. Use glucose, not sucrose, to treat hypoglycemia. Stress. Monitor 1-hour postprandial blood glucose initially and during titration then glycosylated hemoglobin. Pregnancy (Cat.B): consider using insulin instead. Nursing mothers: not recommended.
Antagonized by intestinal adsorbents (eg, charcoal), pancreatin, amylase, other carbohydrate-splitting enzymes. May decrease levels of ranitidine, propranolol. Risk of hypoglycemia with concomitant sulfonylureas or insulin; consider reducing dose of these.
Transient flatulence, diarrhea, abdominal pain; low serum iron.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
- The Caregivers' Cancer Journey
- Staff Education Leads to Increase in Oncology Rehabilitation Referrals
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Gender Bias in Medicine Has Far-Reaching Consequences
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- Patient Interest in Melanoma Genetic Risk Testing is Fairly High
- Genetic Link Between Depression and Breast Cancer Remains Unclear
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|